Curated News
By: NewsRamp Editorial Staff
June 03, 2024

Candel Therapeutics Reports Positive Phase 2 Trial Data for CAN-2409 in Pancreatic Cancer

Reddit Discuss on RedditDiscuss on LinkedIn Discuss on LinkedInDiscuss on Substack Discuss on Substack
Source News Release

TLDR

  • Candel Therapeutics, Inc. reported significant improvement in overall survival in pancreatic cancer patients with CAN-2409 treatment.
  • CAN-2409, an off-the-shelf adenovirus, elicits a systemic immune response in pancreatic cancer patients, leading to improved survival rates.
  • CAN-2409 treatment shows promise in extending the survival of pancreatic cancer patients, offering hope for more effective treatment options in the future.
  • The updated data from Candel Therapeutics' clinical trial demonstrates the potential of CAN-2409 to induce a robust antitumoral immune response in pancreatic cancer.

Impact - Why it Matters

The release of updated survival data from Candel Therapeutics' phase 2 clinical trial of CAN-2409 in pancreatic cancer is significant as it demonstrates promising results in improving overall survival for patients with borderline resectable pancreatic cancer. This could potentially lead to a new treatment option for a disease that accounts for approximately 3% of all cancers in the U.S., impacting thousands of patients each year.

Summary

Candel Therapeutics, Inc. (NASDAQ: CADL) released updated survival data from its phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. The trial indicated very promising results, with patients experiencing a median overall survival of 28.8 months after treatment with CAN-2409, compared to 12.5 months in the control group. No new safety signals were observed, and the therapy was generally well tolerated. The company's lead product candidate, CAN-2409, is an off-the-shelf viral immunotherapy designed to induce a systemic immune response against tumors.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Candel Therapeutics Reports Positive Phase 2 Trial Data for CAN-2409 in Pancreatic Cancer

blockchain registration record for the source press release.